Building the evidence before the therapy arrives

By Published On: October 28, 2026Last Updated: October 28, 2026
Building the evidence before the therapy arrives

Why Sanius Health and the Kielo Research team are focusing on the economic, humanistic and real-world burden of rare disease earlier in drug development

By Orlando Agrippa, CEO, Sanius Health

Across rare disease, the evidence conversation is moving earlier. As more targeted therapies advance towards clinical development, the question is no longer only whether a treatment can change a clinical endpoint.

It is also whether enough evidence has been built, early enough, to understand what that change means for patients, families, regulators, payers and health systems.

This need underpins the new Economic and Humanistic Burden Study in SYNGAP1-Related Disorders, launched by CURE SYNGAP1 in partnership with Global Genes, Kielo Research, a Sanius Health company, and Citizen Health.

The study is expected to include at least 125 caregivers in the United States and will examine areas that traditional clinical measures do not always capture well: quality of life, caregiving, independence, education, employment and the financial impact on families. Families will also be directly involved in developing and testing the survey.

Clinical measurement is necessary, but it is not the whole disease

Medicine has become remarkably sophisticated at measuring disease.

In rare neurodevelopmental disorders, genotype, seizures, developmental delay, motor function, sleep disturbance and other clinical manifestations can be characterised with increasing precision.

Those measures are essential, but they do not necessarily capture the full burden of living with the condition.

SYNGAP1 is a good example. CURE SYNGAP1 has identified more than 1,871 people with the disorder globally.

The clinical phenotype can include epilepsy, intellectual disability, autism spectrum disorder, hypotonia, motor delay, sleep disturbance and gastrointestinal challenges.

Yet the effect of the disease extends well beyond the clinic: it can alter a child’s independence, a parent’s ability to work, the amount of unpaid care a family provides, educational support requirements, household finances and the wellbeing of caregivers.

Those outcomes are not secondary simply because they are harder to measure.

For a payer assessing value, a regulator considering meaningful benefit, or a developer trying to select outcomes for a programme, they can be central to understanding what improvement actually means.

Why timing matters

The timing of this evidence generation is equally important. If the economic and humanistic burden of a disease is only quantified after a therapy reaches the market, the evidence may arrive too late for the decisions that shape access.

Health technology assessment, reimbursement and coverage discussions require credible estimates of disease burden, quality of life, resource use and caregiver impact.

Those datasets cannot always be created retrospectively at speed.

This is one of the most important aspects of the SYNGAP1 programme. The work is being built while the therapeutic landscape is developing, rather than after it. It is intended to create evidence that can support future discussions with regulators, payers, policymakers and therapy developers.

The infrastructure already exists

Another reason the programme is interesting is that it does not start from a blank sheet.

CURE SYNGAP1 already works with Global Genes through the RARE-X platform for its prospective natural history programme and with Citizen Health on retrospective natural history research.

CURE SYNGAP1 reports that more than half of its known US population is already enrolled across these platforms.

That matters because rare disease research repeatedly suffers from fragmentation. Families may contribute to registries, natural history studies, patient-reported outcome projects and individual sponsor studies, while the resulting datasets remain separated.

The opportunity is to build on existing participation and connect different forms of evidence rather than asking the same small populations to start again each time.

Where Sanius Health and Kielo Research fit

This aligns with Sanius Health’s approach to evidence generation.

The company’s work increasingly combines longitudinal clinical information with patient-reported outcomes, wearable-derived physiological signals and real-world data to understand what happens to patients outside conventional study visits.

Kielo Research adds a complementary scientific layer. The team specialises in patient-centred outcomes research, including burden-of-illness studies, patient preference research, clinical outcome assessment development and real-world evidence generation.

Its scientists have authored more than 200 peer-reviewed publications, contributed to regulatory, health technology assessment and payer submissions, and conducted studies in more than 30 countries.

Kielo’s leadership has also been consulted by the US Food and Drug Administration, NICE and the European Commission.

Global Genes will lead the SYNGAP1 study, including survey development, family engagement and data collection through RARE-X.

Kielo will provide health economics expertise in survey methodology and statistical analysis. That is important because the value of a burden study is not simply the number of questions asked.

It is whether those questions generate robust, interpretable evidence that can ultimately sit alongside clinical and real-world datasets.

For Sanius, the opportunity is to connect these disciplines rather than treat them as separate services. Patient-generated data can show how people feel and function over time.

Wearables can provide continuous physiological context. Clinical data can describe treatment, utilisation and disease progression.

Health economics can quantify the wider burden on families and systems. Preference science can identify which benefits, risks and treatment attributes patients value most.

From lived experience to decision-grade evidence

Rare disease research has always depended heavily on patient communities because the populations are small and the lived experience is often dispersed across geographies and health systems.

What is changing is the ability to convert that experience into quantitatively robust evidence.

The new SYNGAP1 study will adapt an existing caregiver burden survey developed for Angelman syndrome to the specific experiences of the SYNGAP1 community.

The planned outputs include a comprehensive report, peer-reviewed manuscript, scientific conference abstract and poster.

That progression matters. Patient centricity cannot simply mean listening to families after the major development decisions have been made.

The strongest model is to involve patients and caregivers early, define the outcomes that matter, quantify the burden rigorously and then carry that evidence forward into development, regulatory, HTA and access discussions.

The next generation of rare disease evidence will not be defined by one dataset.

It will be defined by how well clinical outcomes, natural history, lived experience, patient preferences, economic burden and longitudinal real-world data are connected.

That is the model Sanius Health is continuing to build, with the Kielo Research team adding deep health economics and patient-centred outcomes expertise to an increasingly integrated evidence platform.

As therapies advance, the goal is straightforward: make sure the evidence around the disease develops at the same pace as the science trying to treat it.

Learn more about Sanius Health

New cyber security bill raises stakes for life sciences
Anthropic acquires drug discovery platform Mithril Medicine